Early-stage Asset Prioritization
SITUATION
The Chief Business Officer of a pre-clinical biotechnology company sought to assess the market opportunity for multiple oncology targets and relevant indications to inform strategic portfolio decisions.
OUR ROLE
Our team developed a methodology to evaluate existing treatment pathways, competitor clinical timelines, and efficacy benchmarks across various oncology targets. Through extensive market sizing and clinical outcomes research, we provided actionable cross-target and cross-indication insights to support decision-making and facilitate decisions at an upcoming Board of Directors meeting.
IMPACT
Armed with comprehensive insights across oncology targets and indications, the Chief Business Office presented an asset prioritization plan to the CEO and Board of Directors. Subsequent licensing deals with a top 20 pharmaceutical company validated the effectiveness of our strategic guidance.
